Sort by
Keyphrases
Percutaneous Coronary Intervention
100%
Confidence Interval
79%
Myocardial Infarction
68%
Acute Coronary Syndrome
67%
Aspirin
61%
Clopidogrel
54%
Hazard Ratio
46%
Heart Failure
42%
Meta-analysis
40%
Cardiovascular Mortality
38%
Dual Antiplatelet Therapy
36%
Coronary Artery Disease
36%
Cardiovascular Outcomes
36%
Get With The Guidelines
35%
Type 2 Diabetes Mellitus (T2DM)
35%
Placebo
35%
Atrial Fibrillation
34%
ST-elevation Myocardial Infarction (STEMI)
33%
Acute Myocardial Infarction
33%
Cardiovascular Risk
33%
Atherothrombosis
31%
Major Adverse Cardiovascular Events
30%
Peripheral Arterial Disease
30%
Antiplatelet Therapy
30%
Cardiovascular Disease
29%
Randomized Trial
29%
Odds Ratio
28%
Cardiovascular Events
28%
High Risk
25%
Bleeding
24%
All-cause Mortality
24%
Revascularization
23%
United States
23%
Diabetes
23%
Ticagrelor
23%
Clinical Outcomes
23%
Ischemic Events
22%
Type 2 Diabetic Patients
22%
Randomized Clinical Trial
22%
Secondary Prevention
21%
Ischemic Stroke
20%
Cangrelor
20%
Hospitalization
20%
In-hospital Mortality
20%
Risk Factors
20%
Acute Ischemic Stroke
19%
Icosapent Ethyl
19%
Health Registries
19%
Clinical Trials
18%
Statins
17%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Infarction
88%
Acetylsalicylic Acid
62%
Acute Coronary Syndrome
60%
Cardiovascular Disease
57%
Congestive Heart Failure
57%
Antiplatelet
57%
Cerebrovascular Accident
55%
Clopidogrel
51%
Coronary Artery Disease
48%
Bleeding
48%
Placebo
45%
Maturity Onset Diabetes of the Young
34%
Thrombosis
32%
Diseases
32%
Atrial Fibrillation
30%
Cardiovascular Risk
29%
Brain Ischemia
25%
Acute Heart Infarction
24%
Ticagrelor
22%
Peripheral Occlusive Artery Disease
21%
Randomized Controlled Trial
21%
Diabetes Mellitus
20%
Anticoagulant Agent
20%
Cangrelor
19%
All Cause Mortality
19%
Clinical Trial
19%
Statin (Protein)
18%
Randomized Clinical Trial
18%
ST Segment Elevation Myocardial Infarction
17%
Icosapentaenoic Acid Ethyl Ester
17%
Rivaroxaban
15%
Alirocumab
15%
Coronary Artery Atherosclerosis
15%
Hospital Mortality
13%
Low Density Lipoprotein Cholesterol
12%
Prevalence
12%
Chronic Kidney Failure
12%
Antithrombotic Therapy
12%
Dapagliflozin
12%
Stent Thrombosis
12%
Combination Therapy
11%
Brain Hemorrhage
11%
Fibrinogen Receptor
11%
Warfarin
10%
Inflammation
10%
Atherosclerosis
10%
Antithrombocytic Agent
10%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
10%
Adverse Event
10%
Triacylglycerol
9%
Medicine and Dentistry
Cardiovascular System
72%
Percutaneous Coronary Intervention
71%
Myocardial Infarction
57%
Apoplexy
48%
Congestive Heart Failure
47%
Antiplatelet
45%
Coronary Artery Disease
44%
Acute Coronary Syndrome
42%
Cardiovascular Disease
38%
Meta-Analysis
31%
Odds Ratio
29%
Thrombosis
28%
Hazard Ratio
27%
Brain Ischemia
25%
Bleeding
25%
Cardiovascular Risk
24%
Revascularization
24%
Diseases
24%
Acute Heart Infarction
23%
Maturity Onset Diabetes of the Young
23%
Atrial Fibrillation
23%
Diabetes
23%
ST Segment Elevation Myocardial Infarction
18%
Acetylsalicylic Acid
17%
Placebo
17%
Clinical Trial
17%
Randomized Controlled Trial
17%
Systematic Review
16%
Percutaneous Aortic Valve Replacement
16%
Diabetes Mellitus
15%
Arteriosclerosis Obliterans
15%
Hospital Mortality
14%
Clopidogrel
14%
Combination Therapy
13%
Statin
13%
Drug-Eluting Stent
13%
Randomized Clinical Trials
13%
Chronic Kidney Disease
13%
Arteriosclerotic Heart Disease
13%
Platelet
13%
Coronary Artery Bypass Graft
12%
Antithrombotic
12%
Cangrelor
12%
Outpatient
12%
Blood Pressure
11%
Secondary Prevention
11%
Patient with Type 2 Diabetes
11%
Health Care Cost
10%
Prevalence
10%
Icosapentaenoic Acid Ethyl Ester
10%